Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition)

European Journal of Immunology. doi: 10.1002/eji.202170126

Objective Response Predicts Survival in Advanced Hepatocellular Carcinoma treated with Systemic Therapies

Clinical Cancer Research. doi: 10.1158/1078-0432.CCR-21-3135

Epigenetic priming in chronic liver disease impacts the transcriptional and genetic landscapes of hepatocellular carcinoma

Molecular Oncology. doi: 10.1002/1878-0261.13154

Mapping of population disparities in the cholangiocarcinoma urinary metabolome

Scientific Reports. doi: 10.1038/s41598-021-00530-0

HCV Activates Somatic L1 Retrotransposition-A Potential Hepatocarcinogenesis Pathway

Cancers (Basel). doi: 10.3390/cancers13205079

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Journal of Visual Experiments. doi: 10.3791/62868

Convergent somatic mutations in metabolism genes in chronic liver disease

Nature. doi: 10.1038/s41586-021-03974-6

Efficacy and safety of cabozantinib for patients with advanced hepatocellular carcinoma based on albumin-bilirubin grade

British Journal of Cancer. doi: 10.1038/s41416-021-01532-5

The human liver microenvironment shapes the homing and function of CD4⁺ T-cell populations

Gut. doi: 10.1136/gutjnl-2020-323771

Biopsy for advanced hepatocellular carcinoma: results of a multicentre UK audit

Journal of Breast Cancer. doi: 10.1038/s41416-021-01535-2

Cell-free DNA TAPS provides multimodal information for early cancer detection

Scientific Advances. doi: 10.1126/sciadv.abh0534

Assessment of pegylated arginine deiminase and modified FOLFOX6 in patients with advanced hepatocellular carcinoma: Results of an international, single-arm, phase 2 study

Cancer. doi: 10.1002/cncr.33870

Key features of the environment promoting liver cancer in the absence of cirrhosis

Scientific Reports. doi: 10.1038/s41598-021-96076-2

Upregulation of C/EBPα Inhibits Suppressive Activity of Myeloid Cells and Potentiates Antitumor Response in Mice and Patients with Cancer

Clinical Cancer Research. doi: 10.1158/1078-0432.CCR-21-0986

Prognostic Value and Potential Immunoregulatory Role of SCARF1 in Hepatocellular Carcinoma

Frontiers in Oncology. doi: 10.3389/fonc.2020.565950

Effect of Hepatocellular Carcinoma Surveillance Programmes on Overall Survival in a Mixed Cirrhotic UK Population: A Prospective, Longitudinal Cohort Study

Journal of Clinical Medicine. doi: 10.3390/jcm10132770

Transcriptomic characterization of cancer-testis antigens identifies MAGEA3 as a driver of tumor progression in hepatocellular carcinoma

PLoS Genetics. doi: 10.1371/journal.pgen.1009589

Immunomodulatory Effects of Lenvatinib Plus Anti-Programmed Cell Death Protein 1 in Mice and Rationale for Patient Enrichment in Hepatocellular Carcinoma

Hepatology. doi: 10.1002/hep.32023

Editorial: Overcoming the Immune Microenvironment of Hepatocellular Cancer

Frontiers in Immunology. doi: 10.3389/fimmu.2021.707329

Evidence-Based Management of Hepatocellular Carcinoma: Systematic Review and Meta-analysis of Randomized Controlled Trials (2002-2020)

Gastroenterology. doi: 10.1053/j.gastro.2021.06.008

Pharmacodynamic Biomarkers Predictive of Survival Benefit with Lenvatinib in Unresectable Hepatocellular Carcinoma: From the Phase III REFLECT Study

Clinical Cancer Research. doi: 10.1158/1078-0432.CCR-20-4219

Sorafenib is associated with a reduced rate of tumour growth and liver function deterioration in HCV-induced hepatocellular carcinoma

Journal of Hepatology. doi: 10.1016/j.jhep.2021.05.015

Anti-miR-518d-5p overcomes liver tumor cell death resistance through mitochondrial activity

Cell Death & Disease. doi: 10.1038/s41419-021-03827-0

Clonally expanded EOMES⁺ Tr1-like cells in primary and metastatic tumors are associated with disease progression

Nature Immunology. doi: 10.1038/s41590-021-00930-4

Peptide: MHC-based DNA vaccination strategy to activate natural killer cells by targeting killer cell immunoglobulin-like receptors

Journal of ImmunoTherapy of Cancer. doi: 10.1136/jitc-2020-001912

Natural Killer Cells and Regulatory T Cells Cross Talk in Hepatocellular Carcinoma: Exploring Therapeutic Options for the Next Decade

Frontiers in Immunology. doi: 10.3389/fimmu.2021.643310

Molecular characterisation of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis

Journal of Hepatology. doi: 10.1016/j.jhep.2021.04.049

Targeting human Acyl-CoA:cholesterol acyltransferase as a dual viral and T cell metabolic checkpoint

Nature Communications. doi: 10.1038/s41467-021-22967-7

NAFLD-Associated HCC: Progress and Opportunities

Journal of Hepatocellular Carcinoma. doi: 10.2147/JHC.S272213

A PDCD1 Role in the Genetic Predisposition to NAFLD-HCC?

Cancers (Basel). doi: 10.3390/cancers13061412

Neutrophils induce paracrine telomere dysfunction and senescence in ROS-dependent manner

EMBO Journal. doi: 10.15252/embj.2020106048

NASH limits anti-tumour surveillance in immunotherapy-treated HCC

Nature. doi: 10.1038/s41586-021-03362-0

Primary liver cancer in the UK: Incidence, incidence-based mortality, and survival by subtype, sex, and nation

JHEP Reports. doi: 10.1016/j.jhepr.2021.100232

COX2 regulates senescence secretome composition and senescence surveillance through PGE₂

Cell Reports. doi: 10.1016/j.celrep.2021.108860

DNA Methylation Signatures Reveal the Diversity of Processes Remodeling Hepatocellular Carcinoma Methylomes

Hepatology. doi: 10.1002/hep.31796

International Liver Cancer Association (ILCA) White Paper on Biomarker Development for Hepatocellular Carcinoma

Gastroenterology. doi: 10.1053/j.gastro.2021.01.233

Assessing the impact of COVID-19 on liver cancer management (CERO-19)

JHEP Reports. doi: 10.1016/j.jhepr.2021.100260

Hepatocellular carcinoma in non-alcoholic fatty liver disease-a review of an emerging challenge facing clinicians

Hepatobiliary Surgery & Nutrition. doi: 10.21037/hbsn.2019.08.08

Serum alpha-fetoprotein and clinical outcomes in patients with advanced hepatocellular carcinoma treated with ramucirumab

British Journal of Cancer. doi: 10.1038/s41416-021-01260-w

Liver Injury Increases the Incidence of HCC following AAV Gene Therapy in Mice

Molecular Therapy. doi: 10.1016/j.ymthe.2020.10.018

Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma

Nature Reviews Gastroenterology & Hepatology. doi: 10.1038/s41575-020-00395-0

Hepatocellular carcinoma

Nature Reviews Disease Primers. doi: 10.1038/s41572-021-00245-6

Atezolizumab plus Bevacizumab: A Novel Breakthrough in Hepatocellular Carcinoma

Clinical Cancer Research. doi: 10.1158/1078-0432.CCR-20-4706

Diagnosis and treatment of hepatocellular carcinoma. Update of the consensus document of the AEEH, AEC, SEOM, SERAM, SERVEI, and SETH

Medicina Clínica. doi: 10.1016/j.medcli.2020.09.022

Treatment strategies for early stage hepatocellular carcinoma: a systematic review and network meta-analysis of randomised clinical trials

HPB. doi: 10.1016/j.hpb.2020.10.031

Nutlin-3a Enhances Natural Killer Cell-Mediated Killing of Neuroblastoma by Restoring p53-Dependent Expression of Ligands for NKG2D and DNAM-1 Receptors

Cancer Immunology Research. doi: 10.1158/2326-6066.CIR-20-0313

Viral and immune factors associated with successful treatment withdrawal in HBeAg-negative chronic hepatitis B patients

Journal of Hepatology. doi: 10.1016/j.jhep.2020.11.043

Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores

Journal of Hepatology. doi: 10.1016/j.jhep.2020.11.024

DNA Methylation Profiling of Human Hepatocarcinogenesis

Hepatology. doi: 10.1002/hep.31659

Pattern of progression in advanced hepatocellular carcinoma treated with ramucirumab.

Liver International. doi: 10.1111/liv.14731

CD8⁺ T cells specific to apoptosis-associated epitopes are expanded in patients with chronic HBV infection and fibrosis

Liver International. doi: 10.1111/liv.14720

Mutations in circulating tumor DNA predict primary resistance to systemic therapies in advanced hepatocellular carcinoma

Oncogene. doi: 10.1038/s41388-020-01519-1

TREM-2 defends the liver against hepatocellular carcinoma through multifactorial protective mechanisms

Gut. doi: 10.1136/gutjnl-2019-319227

On the impact of hepatitis C virus and heterologous immunity on alloimmune responses following liver transplantation

American Journal of Transplantation. doi: 10.1111/ajt.16134

Impact of donor extracellular vesicle release on recipient cell "cross-dressing" following clinical liver and kidney transplantation

American Journal of Transplantation. doi: 10.1111/ajt.16123

Lipid Remodeling in Hepatocyte Proliferation and Hepatocellular Carcinoma

Hepatology. doi: 10.1002/hep.31391

Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference

Hepatology. doi: 10.1002/hep.31327

Serum Levels of α-Fetoprotein Increased More Than 10 Years Before Detection of Hepatocellular Carcinoma

Clinical Gastroenterology & Hepatology. doi: 10.1016/j.cgh.2020.04.084